PCSS-MAT Half-and-Half Buprenorphine Waiver Training - Providers' Clinical Support System for Medication Assisted Treatment
Online and Live Blended Course
A collaboration between the Massachusetts Medical Society (MMS) and The American Society of Addiction Medicine (ASAM)
1:00 p.m. - 5:30 p.m.
Cost: FREE
The American Society of Addiction Medicine (ASAM) is pleased to collaborate with the Massachusetts Medical Society (MMS) to bring the PCSS-MAT Buprenorphine Waiver Training to MMS Headquarters in Waltham, MA on Thursday, November 17, 2016. Led by expert faculty, the course will cover the use of buprenorphine in the treatment of opioid use disorder in office-based practices.
1st Half of the Course
3.75 hours of online training on substance use treatment, opioids, and the use of buprenorphine in the treatment of opioid use disorders from office-based practices. An examination must be successfully completed to obtain a waiver for prescribing buprenorphine.
2nd Half of the Course
A face-to-face, classroom-style training in a 4.25 hour training. The training focuses on specifics of treating patients with opioid use disorders in office-based settings and clinical vignettes to help trainees think through “real life” experiences in opioid use disorders treatment.
The Drug Abuse Treatment Act of 2000 (DATA 2000) requires physicians to obtain a waiver to engage in office-based treatment of opioid use disorders using drugs on Schedules III, IV and V. This activity also meets pain management CME criteria for physicians licensed in Massachusetts.
For more information please call 781-434-7306 or email ContinuingEducation@massmed.org. To register online, click the "individual registration" button above.
Note: Funding for this initiative was made possible (in part) by Providers' Clinical Support System for Medication Assisted Treatment (grant nos. 5U79TI024697 and 1U79TI026556) from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
Learning Objectives:
After participating in this activity, you should be able to:
- Apply for a waiver to prescribe buprenorphine to your patients with opioid use disorders
- Identify and assess patients who are appropriate for treatment with buprenorphine
- Have specific knowledge concerning the use of buprenorphine to manage opioid addicted patients
- Discuss the psychiatric and medical co-morbidities associated with opioid addiction
Target Audience:
Physicians, Nurse Practitioners, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorders; clinicians and health care team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorders
ACCME Accreditation Statement:
The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The American Society of Addiction Medicine designates this enduring material activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their parti